Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Fukujin, Seiwa Sangyo Form Business Alliance
September 20, 2004
- Bushu Pharmaceuticals Expanding Contract Manufacturing System
September 20, 2004
- Chugai to Establish Clinical Development Subsidiary
September 20, 2004
- Norvasc Ranks Top in 1st Half of 2004: IMS Data
September 20, 2004
- BI Reinforcing Independent Marketing System, Particularly in US: Dr Banchi
September 20, 2004
- Human ES Cells to Reduce Cost, Risk of Clinical Trials: PMSRL Seminar
September 20, 2004
- J&J to Strengthen Collaboration between 6 Subsidiaries in Japan: Mr Perkins
September 20, 2004
- BULLETIN
September 20, 2004
- MONITOR
September 20, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 20, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 20, 2004
- Health Science Research Group Surveying State of IRBs in Japan
September 20, 2004
- OTC NEWS IN BRIEF
September 20, 2004
- Switching to Olanzapine Monotherapy Improves QOL: Eli Lilly Japan
September 20, 2004
- NEW PRODUCTS
September 20, 2004
- The 7th International Symposium on Clinical Trials
September 20, 2004
- GEYMS: World's First Volume CT LightSpeed VCT
September 20, 2004
- Ban on Internet Drug Sales Notified
September 20, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 20, 2004
- 67.7% of People Wish to See Reform of Social Insurance Programs: Public Opinion Poll
September 20, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…